The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
Ozempic, Wegovy and other GLP-1 drugs are being investigated as treatments for many health conditions—from dementia to ...
Medicare (and Medicare Advantage) provide some coverage for dementia, beginning with the diagnosis, says Baumgart.
Earnings for healthcare companies have declined for six straight quarters. But analysts have a more positive outlook going ...
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan ...
Simon said these newly FDA-approved drugs alters the disease itself, slowing down Alzheimer's for those that have it or have ...
It was a regular week for the biotech sector with quite a few important pipeline and regulatory updates. Among these, Cassava Sciences, Inc. SAVA and Lexeo Therapeutics LXEO were down on leadership ...
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
ASX health stocks continue to have a strong start to FY25 as Morgans senior analyst Scott Power says there are strong signs ...
The stock market continues to demonstrate strong performance, with the Dow Jones recently achieving a new record high above ...
Roche’s recent $2.7 billion acquisition of Carmot Therapeutics is paying off, with positive results for new oral GLP-1 ...